Research peptides for longevity, telomere health and mitochondrial function.

LongevityPeptides.co.uk is an independent editorial resource. We do not sell peptides. Every entry on the site summarises published preclinical and clinical evidence, identifies mechanism, gives the safety profile reported in the literature, and frames the UK regulatory status accurately — none of the peptides discussed are licensed medicines in the UK, and all are supplied for laboratory and research use only.

"Longevity peptides" is a broad and often loosely used term, so we define our scope explicitly. The site covers signalling peptides with published evidence relevant to ageing biology, organised into six mechanistic categories: telomere and pineal-signalling peptides, mitochondrial-support peptides, growth-hormone-axis secretagogues, thymic and immune-modulating peptides, cellular-repair peptides, and compounds implicated in NAD⁺ and sirtuin pathways. A peptide is only added once there is an identifiable body of preclinical or clinical literature to summarise — we do not create entries around marketing claims alone.

The UK regulatory context shapes how every entry is written. Under the Human Medicines Regulations 2012, a product is a medicine if it is presented as treating or preventing disease, or if it exerts a pharmacological, immunological or metabolic effect and is administered with that intent; the MHRA has not granted a marketing authorisation to any peptide discussed on this site for longevity or anti-ageing use. We therefore consistently use research-chemical framing rather than clinical or therapeutic language, and we flag clearly where a peptide has approved indications abroad but not in the UK, or where its only human data comes from small, non-UK trials.

Sourcing follows a consistent hierarchy. Peer-reviewed findings indexed on PubMed take precedence, followed by systematic reviews and meta-analyses, then guidance or safety communications from regulators such as the MHRA, EMA and FDA, then entries in clinical trial registries such as ClinicalTrials.gov. Where the only available evidence is an open-label or observational cohort — common in this field, particularly for older Russian and Eastern European peptide research — we say so explicitly rather than presenting it with the weight of a randomised controlled trial.

We also try to represent genuine scientific disagreement rather than smoothing it over. The GH-axis category discusses the IGF-1 longevity paradox, where the same signalling that supports growth and repair in youth is associated with accelerated ageing markers and higher cancer risk when chronically elevated in later life. Telomerase-inducing compounds are presented alongside the theoretical concern that lengthening telomeres indiscriminately could support proliferation of damaged or senescent cells. And where a peptide's core evidence base originates largely from one research group — as with several of Vladimir Khavinson's bioregulator peptides — we note that independent replication outside that group remains limited, rather than treating the original studies as settled.

For researchers and laboratories sourcing reference material, two UK suppliers active in the research-peptide market are PeptideAuthority.co.uk and PeptideBarn.co.uk. We link to them because their catalogues and analytical certificates are publicly available, not because of any commercial arrangement — this site carries no advertising, no affiliate links and no paid placements, and no supplier has any influence over editorial content.

If you are new to the field, the Epitalon and GHK-Cu entries are the most comprehensive starting points, with the deepest published research base. For a comparative overview, see our comparisons section; for guidance on how peptides are discussed together for specific research contexts, see our protocol overviews; and for plain-English summaries of the underlying studies, see the research index.